Therefore, as EP4 is a more specific downstream signaling molecule of COX-2/PGE2, targeting EP4 is promising for suppressing inflammation-related CRC development with fewer adverse effects [14,15]. This evidence concerns the gene PTGER4 and colorectal carcinoma.